The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe.
Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries, employing over 8,600 people and generating annual revenues in excess of $3.4 billion.
We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.
We are global leaders in pain medicine, with a significant and growing presence in our three other core therapeutic areas of respiratory, oncology and biosimilars. However, we are also open to new partnership opportunities that will enable us to realize the potential of medicines at all stages of maturity across other therapy areas.
Press return to search